The CMR Green Technologies IPO GMP (Grey Market Premium) has started in the grey market,…
Goldline Pharmaceutical IPO GMP Day-2: Grey Market Premium
Goldline Pharmaceutical SME IPO last GMP is ₹18, last updated May 13th 2026 09:00 AM. With the price band of ₹43.00, Goldline Pharmaceutical SME IPO’s estimated listing price is ₹61 (cap price + today’s GMP). The expected percentage gain/loss per share is 41.86%. Goldline Pharmaceutical SME IPO Retail Subject to Sauda is ₹41000.
We update GMP on a daily basis and based on the last 7 sessions of grey market activity, today’s IPO GMP trend is moving upward and indicating expectations of a strong listing. The lowest GMP recorded is ₹0.00, while the highest GMP reached ₹18.00. Stay connected with us for daily updates on Goldline Pharmaceutical SME IPO GMP and the expected listing price trend.
Goldline Pharmaceutical IPO GMP Live Rates day by day.
| Date | IPO GMP | GMP Trend | Gain |
|---|---|---|---|
| 13 May | ₹18 |  |
41.86% |
| 12 May | ₹17 | |
39.53% |
| 11 May | ₹16 | |
37.21% |
| 9 May | ₹8 | |
18.60% |
| 8 May | ₹7 | |
16.28% |
| 7 May | ₹- | – | -% |
RFBL Flexi Pack IPO Details
| IPO Open Date | May 12, 2026 |
| IPO Close Date | May 14, 2026 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹41 to ₹43 Per Share |
| Issue Size | Approx ₹12 Crores |
| Fresh Issue | Approx ₹12 Crores |
| Issue Type | Book build Issue |
| IPO Listing | BSE SME |
RFBL Flexi Pack IPO Dates
| IPO Open Date | May 12, 2026 |
| IPO Close Date | May 14, 2026 |
| Basis of Allotment | May 15, 2026 |
| Refunds | May 18, 2026 |
| Credit to Demat Account: | May 18, 2026 |
| IPO Listing Date: | May 19, 2026 |
| IPO Bidding Cut-off Time: | May 14, 2026 – 5 PM |
Company Overview
Goldline Pharmaceutical Ltd. is a rapidly growing pharmaceutical company established on 28 February 2005 and headquartered in Nagpur, Maharashtra. Founded by Mr. Amol Mujumdar, the company has expanded its operations across 9 Indian states including Maharashtra, Chhattisgarh, Madhya Pradesh, Odisha, Tamil Nadu, Rajasthan, Jharkhand, Goa, and Bihar. The company focuses on delivering high-quality therapeutic products while continuously strengthening its market presence through innovation, customer satisfaction, and efficient marketing strategies.
Goldline Pharmaceutical operates with a dedicated marketing and product management team that regularly updates its portfolio with new formulations and advanced drug delivery systems. The company has successfully introduced products such as C-2, TROTFIT, ENTIAL, LUKIN NXT, and MYTIFY JUNIOR, which have received strong responses from medical professionals. With a strong focus on employee development, operational excellence, and sustainable growth, Goldline Pharmaceutical continues to strengthen its position in the Indian pharmaceutical industry.
Related Posts
